Actinic keratosis (AK) has a negative impact on patients’ physical and psychological quality of life due to disease chronicity, fear of progression to keratinocyte carcinoma, and effect on cosmetic appearance.

Methyl aminolevulinate (MAL), used as a topical precursor in conjunction with photodynamic therapy (PDT), is an approved and recommended treatment option for patients with AK in certain countries.

As a field-directed therapy, MAL-PDT has demonstrated high efficacy in clearing AK lesions with low recurrence rates, is generally well tolerated, and provides favorable cosmetic outcomes.

MAL-PDT is a safe and effective treatment option for both immunocompetent patients and those who are immunosuppressed, such as organ transplant recipients, with or without additional pre-treatments.

MAL is efficacious when used in conjunction with any of the available PDT modalities (conventional, daylight, or artificial daylight).

AK is a chronic disease requiring repeated treatment sessions; MAL-PDT provides flexible treatment strategies to suit the needs of the patient, potentially optimizing treatment adherence.